Nagayama S - Search Results

1

Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.

Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, Takenaka O, Inoda T, Kashiyama E, Aoyama A, Nakabayashi T, Omori S, Kuwabara T, Izumi T, Nakamura K, Takanaka K, Nakayama Y, Takeuchi M, Nakamura H, Kametani S, Terauchi Y, Hashizume T, Nagayama S, Kume T, Achira M, Kawai H, Kawashiro T, Nakamura A, Nakai Y, Kagayama A, Shiraga T, Niwa T, Yoshimura T, Morita J, Ohsawa F, Tani M, Osawa N, Ida K, Noguchi K. Iwasaki M, et al. Among authors: nagayama s. Drug Metab Pharmacokinet. 2004 Dec;19(6):444-52. doi: 10.2133/dmpk.19.444. Drug Metab Pharmacokinet. 2004. PMID: 15681899 Free article.

2

Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.

Kitamura R, Matsuoka K, Nagayama S, Otagiri M. Kitamura R, et al. Among authors: nagayama s. Drug Metab Pharmacokinet. 2008;23(6):421-7. doi: 10.2133/dmpk.23.421. Drug Metab Pharmacokinet. 2008. PMID: 19122336 Free article.

3

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.

Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T. Daigo S, et al. Among authors: nagayama s. Pharmacogenetics. 2002 Jun;12(4):299-306. doi: 10.1097/00008571-200206000-00005. Pharmacogenetics. 2002. PMID: 12042667

4

Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.

Yamamiya I, Yoshisue K, Matsushima E, Nagayama S. Yamamiya I, et al. Among authors: nagayama s. Drug Metab Dispos. 2010 Aug;38(8):1267-76. doi: 10.1124/dmd.110.032797. Epub 2010 May 12. Drug Metab Dispos. 2010. PMID: 20463005

5

TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.

Matsuoka-Kawano K, Yoshinari K, Nagayama S, Yamazoe Y. Matsuoka-Kawano K, et al. Among authors: nagayama s. Chem Biol Interact. 2010 Apr 15;185(1):33-41. doi: 10.1016/j.cbi.2010.02.014. Epub 2010 Feb 18. Chem Biol Interact. 2010. PMID: 20171196

6

Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y. Ikeda K, et al. Among authors: nagayama s. Clin Cancer Res. 2000 Nov;6(11):4409-15. Clin Cancer Res. 2000. PMID: 11106261

7

Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.

Tsuchiya H, Kuwata K, Nagayama S, Yamashita K, Kamiya H, Harashima H. Tsuchiya H, et al. Among authors: nagayama s. Drug Metab Pharmacokinet. 2004 Jun;19(3):206-15. doi: 10.2133/dmpk.19.206. Drug Metab Pharmacokinet. 2004. PMID: 15499188 Free article.

8

Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68).

Kitamura R, Asanoma H, Nagayama S, Otagiri M. Kitamura R, et al. Among authors: nagayama s. Drug Metab Dispos. 2008 Jun;36(6):1003-9. doi: 10.1124/dmd.107.019877. Epub 2008 Mar 5. Drug Metab Dispos. 2008. PMID: 18322074

9

Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor.

Yamaya H, Saeki M, Yoshida K, Shibata J, Yano S, Sato Y, Takao A, Shindo T, Buzdar AU, Nagayama S. Yamaya H, et al. Among authors: nagayama s. Drug Metab Dispos. 2006 Feb;34(2):331-8. doi: 10.1124/dmd.105.005504. Epub 2005 Nov 18. Drug Metab Dispos. 2006. PMID: 16299166

10

Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats.

Kitamura R, Yamamoto Y, Nagayama S, Otagiri M. Kitamura R, et al. Among authors: nagayama s. Drug Metab Dispos. 2007 Sep;35(9):1611-6. doi: 10.1124/dmd.106.014068. Epub 2007 Jun 13. Drug Metab Dispos. 2007. PMID: 17567729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

395 results

Search Page